参考文献/References:
[1] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会,中国房颤中心联盟心房颤动防治专家工作委员会.心房颤动:目前的认识和治疗建议(2021)[J].中华心律失常学杂志,2022,26(1):15-88.
[2] FRANCO L,BECATTINI C,BEYER-WESTENDORF J,et al.Definition of major bleeding:prognostic classification[J]. J Thromb Haemost,2020,18(11):2852-2860.
[3] HYLEK E M,HELD C,ALEXANDER J H,et al.Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin:The ARISTOTLE Trial(apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation):predictors,characteristics,and clinical outcomes[J].J Am Coll Cardiol,2014,63(20):2141-2147.
[4] BAHIT M C,LOPES R D,WOJDYLA D M,et al.Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation[J].Heart,2017,103(8):623-628.
[5] HIJAZI Z,OLDGREN J,LINDBACK J,et al.The novel biomarker-based ABC(age,biomarkers,clinical history)-bleeding risk score for patients with atrial fibrillation:a derivation and validation study[J].Lancet,2016,387(10035):2302-2311.
[6] PATTI G,PECEN L,MANU M C,et al.Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies[J].Int J Cardiol,2020(318):67-73.
[7] MARTIN K,BEYER-WESTENDORF J,DAVIDSON B L,et al.Use of the direct oral anticoagulants in obese patients:guidance from the SSC of the ISTH[J].J Thromb Haemost,2016,14(6):1308-1313.
[8] KRITTAYAPHONG R,CHICHAREON P,KOMOLTRI C,et al.Low body weight increases the risk of ischemic stroke and major bleeding in atrial fibrillation:the COOL-AF registry[J/OL].[2021-07-05].https://www.mdpi.com/2077-0383/9/9/2713.DOI:10.3390/jcm9092713.
[9] O'BRIEN E C,SIMON D N,THOMAS L E,et al.The ORBIT bleeding score:a simple bedside score to assess bleeding risk in atrial fibrillation[J].Eur Heart J,2015,36(46):3258-3264.
[10]WANG C L,WU V C,CHANG K H,et al.Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs[J].Eur Heart J Cardiovasc Pharmacother,2020,6(3):147-154.
[11]CHANG S H,CHOU I J,YEH Y H,et al.Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation[J].JAMA,2017,318(13):1250-1259.
[12]JUNG M,LEE S.Effects of statin therapy on the risk of intracerebral hemorrhage in Korean patients with hyperlipidemia[J].Pharmacotherapy,2019,39(2):129-139.
[13]LI B Z,THREAPLETON D E,WANG J Y,et al.Comparative effectiveness and tolerance of treatments for helicobacter pylori:systematic review and network meta-analysis[J/OL].[2021-07-05].https://www.bmj.com/content/351/bmj.h4052.long.DOI:10.1136/bmj.h4052.
[14]HILL K,SUCHA E,RHODES E,et al.Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants[J].JAMA Intern Med,2020,180(8):1052-1060.
[15]VIOLI F,LIP G Y,PIGNATELLI P,et al.Interaction between dietary vitamin K intake and anticoagulation by vitamin K antagonists:is it really true?:a systematic review[J/OL].[2021-07-05].https://journals.lww.com/md-journal/Fulltext/2016/03080/Interaction_Between_Dietary_Vitamin_K_Intake_and.23.aspx.DOI:10.1097/MD.0000000000002895.
[16]卢冰清,汪小华,杨小芳,等.房颤服用华法林患者自我管理现状调查及影响因素分析[J].中国护理管理,2018,18(11):1535-1539.
[17]王广宁,崔岩,杨富国,等.房颤患者华法林自我管理现状及影响因素调查[J].护理学杂志,2019,34(11):5-8.
[18]汪露.健康信念模式改进心脏机械瓣膜置换术后抗凝管理效果的研究[D].南京:南京中医药大学,2015.
[19]韦兆玲,张丽红.房颤患者口服华法林抗凝管理的现状与展望[J].,2017,34(11):37-39.
[20]SALMASI S,KWAN L,MACGILLIVRAY J,et al.Assessment of atrial fibrillation patients' education needs from patient and clinician perspectives:a qualitative descriptive study[J].Thromb Res,2019(173):109-116.
[21] GAGE B F,WATERMAN A D,SHANNON W,et al.Validation of clinical classification schemes for predicting stroke:results from the national registry of atrial fibrillation[J].JAMA,2001,285(22):2864-2870.
[22]LIP G Y H,ANDREOTTI F,FAUCHIER L,et al.Bleeding risk assessment and management in atrial fibrillation patients.Executive summary of a position document from the European Heart Rhythm Association [EHRA],endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis[J].Thromb Haemost,2011,106(6):997-1011.
[23]ROLDAN V,MARIN F,MANZANO-FERNANDEZ S,et al.The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation[J].J Am Coll Cardiol,2013,62(23):2199-2204.
[24]PISTERS R,LANE D A,NIEUWLAAT R,et al.A novel user-friendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey[J].Chest,2010,138(5):1093-1100.
[25]LIP G Y,LANE D A.Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores:clinical application requires focus on the reversible bleeding risk factors[J].Eur Heart J,2015,36(46):3265-3267.
[26]FANOLA C L,GIUGLIANO R P,RUFF C T,et al.A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial[J].Eur Heart J,2017,38(12):888-896.
[27]RIVERA-CARAVACA J M,ROLDAN V,ESTEVE-PASTOR M A,et al.Prediction of long-term net clinical outcomes using the TIMI-AF score:comparison with CHA2DS2-VASc and HAS-BLED[J].Am Heart J,2018(197):27-34.